Cyberonics — FY2003 Earnings Presentation
35 slides from Cyberonics's earnings presentation, Jun 18, 2003
Slide 1: The Evolution of the CYBX Opportunity
The Evolution of the CYBX Opportunity: From Pioneering to Predictable and Profitable Growth With or Without Depression FY03: A Year for the Record Books FY04 Plan: Improving Productivity and Profitability to Increase Scalability and Transferability to Fully Realize Our Opportunities in Epilepsy and
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation may include forward-looking statements concerning revised guidance for fiscal 2004 relating to anticipated sales, gross profit margin, operating expenses and earnings, net income, profits and earnings per share investments in new indication development, m
Slide 3: The Mission Demanded Pioneering
The Mission Demanded Pioneering New medical science regarding the vagus nerve and its impact on neurotransmitters and brain function; New nerve stimulation devices; New device based therapy; New device study protocols; New FDA Approval process; New sales and marketing organization and model to creat
Slide 4: Beyond Pioneering into Predictable and Profitable Growth
Beyond Pioneering into Predictable and Profitable Growth FY03 performance and FY04 plan confirm that Cyberonics and VNS Therapy have moved beyond pioneering into a period of predictable and profitable growth. The core competencies that Cyberonics developed during its years of pioneering will facilit
Slide 5: Strong Device Team
Strong Device Team Name Position Yrs Experience; (joined CYBX) Previous Companies (Products) Shawn Lunney VP-Market Dev. 15 (1991) CYBX Alan Totah VP-Regulatory & QA 30 (2001) Medtronic, Intermedics Pam Westbrook VP-Finance, CFO 20 (1998) Intermedics Scott Armstrong Director, Electrical Engineering
Slide 6: Strong Pharmaceutical Team
Strong Pharmaceutical Team Name Position Yrs Experience; (joined CYBX) Previous Companies (Products) Michael Cheney Senior VP-Marketing and Sales 19 (2001) Knoll/BASF Pharma, Wyeth-Ayerst, Scios-Nova Steve Jennings VP-Sales 26 (2003) Solvay, CIBA-GEIGY Richard Rudolph, M.D. VP-Medical and Clinical A
Slide 7: FY03: >$100M Sales Milestone
FY03: >$100M Sales Milestone FY98 FY99 FY00 FY01 FY02 FY03 Worldwide Sales ($$ in Millions) 103% 6 yr Sales CAGR from US launch (1997) thru FY03 49% annual growth for FY03 Beat FY03 budget by 16% Beat Street guidance/consensus in 7 of last 8 quarters; missed Q4 guidance by 0.8%, Q4 consensus by 4%
Slide 8: FY03: First Profitable and Cash Flow Positive Year
FY03: First Profitable and Cash Flow Positive Year FY03 bottom line increased by 118% to $0.22 per share FY03 net increased $31.3M on $34.4M sales increase = 91% drop-thru Beat FY03 budget by $24M (128%) Beat Street guidance and consensus for 8 consecutive quarters $5.3M of positive cash flow = $43.
Slide 9: Published VNS Therapy literature
The evolving place of vagus nerve stimulation therapy Steven C. Schachter and James W. Wheless Therapeutic mechanism of vagus nerve stimulation Thomas R. Henry Vagus nerve stimulation therapy summary: Five years after FDA Approval Steven C. Schachter Vagus nerve stimulation therapy in patients young
Slide 10: FY03: High Margin Device Technology and Manufacturing Process
FY03: High Margin Device Technology and Manufacturing Process Device Technology Entirely new higher priced ($14,497 vs. $12,250), lower cost product family launched in Q1 First product designed and manufactured entirely by CYBX >90% of eligible demand converted within 3 months Model 103 on schedule
Slide 11: FY03: Increasingly Predictable and Profitable Sales Model
Patient Identification and Qualifications (PIQs) FY03: Increasingly Predictable and Profitable Sales Model Office Patient Education OPE Implant Surgeon Consult FTF: Sales Reps with Prescribers FTF: National Account Managers on Key Accounts Marketing Programs for Clinicians and Patients OR Additions
Slide 12: FY03: Sufficiently Scalable and Transferable?
FY03: Sufficiently Scalable and Transferable? We compare US Sales and Marketing expenses as a percent of sales with US Contribution Margin ((US Gross Profit - US S&M expenses)/US Sales) to determine profitability and scalability. The last major expansion of U.S. sales occurred in Q3 FY02. One year l
Slide 13: FY03: US Sales Expansion and Realignment
FY03: US Sales Expansion and Realignment Refined targeting increased prescriber market to xxxx MDs New more experienced management hired (VP-Sales, 2 GBU Directors, 2 Regional Managers); Field sales management streamlined 41 Territories converted into 84 Territories with maximum 100 mile working rad
Slide 14: U.S. Sales Force Expansion and Re-Alignment
The expansion and realignment of Cyberonics' U.S. sales organization has increased cost effective reach and frequency with a reduced US S&M headcount consistent with customers' needs. U.S. Sales Force Expansion and Re-Alignment Resources Before After Total U.S. sales headcount 131 120 Total territor
Slide 15: FY03/4: Cost-Effective New Indications Development
FY03/4: Cost-Effective New Indications Development Clinical and Medical Affairs Upgraded people and organization Significantly improved productivity and efficiency as measured by expenses as a percent of sales and per unit Achieved all depression objectives Depression Safety and tolerability of impl
Slide 16: FY04: Depression Objectives
FY04: Depression Objectives In January 2003, CYBX reported statistically and clinically significant one year results thereby reaching Base Camp in its six step climb to U.S. Depression regulatory approval. This positive make-or-break first step while essential does not guarantee that we will reach t
Slide 17: FY04: Depression Regulatory Observations
FY04: Depression Regulatory Observations In 2002, the average PMA approval time was 364 days VNS is the first anti-depressant treatment to be granted Expedited Review Status; FDA understands and owns the need for new and better treatments for treatment resistant depression The submission will likely
Slide 18: FY03/4: Maximizing Return on Equity
FY03/4: Maximizing Return on Equity Most recent offering = $45M Feb 2001 PIPE Total equity raised from all sources ~ $175M Total proceeds from option exercises and employee stock purchase plan ~ $19M Cash on 4/25/03 ~ $44M Net equity capital used ~ $131M Net outside equity capital used ~ $112M Total
Slide 19: FY04 Budget Summary
FY04 Budget Summary To accomplish our mission in FY04, we are planning to leverage our core competencies to increase the productivity, profitability and return on existing resources and investments to improve the scalability of our business model in epilepsy and transferability of that model to depr
Slide 20: FY03 Financial Performance Summary
FY03 Financial Performance Summary $ in 000's. except EPS Original May02 Guidance * FY03 Results Sales $90,000 $104,467 Annual sales growth 28.4% 49.0% Gross Margin 81.9% 84.6% OPEX as a % of sales 102.9% 80.1% Net Income (Loss) ($18,700) $5,185 EPS, fully diluted ($0.85) $0.22 Sustainable Profitabi
Slide 21: Worldwide Sales
Worldwide Sales Quarter Ended 4/25/03 61% of sales growth is driven by increases in unit sales 39% of sales growth due to higher ASP's and product mix Year Ended 4/25/03 67% of sales growth is driven by increases in unit sales 33% of sales growth due to higher ASP's and product mix Annual sales grow
Slide 22: U.S. Sales
U.S. Sales Quarter Ended 4/25/03 52% of sales growth is driven by increases in unit sales 48% of sales growth due to higher ASP's and product mix Year Ended 4/25/03 66% of sales growth is driven by increases in unit sales 34% of sales growth due to higher ASP's and product mix Annual U.S. sales grow
Slide 23: Gross Profit Margin
Gross Profit Margin Gross Profit Margin was significantly higher than last year as a result of higher average selling prices, increasing volume, lower production costs and increased demand for replacement generators. Quarter Ended 4/25/03 GPM increased by 184 basis points over prior year Production
Slide 24: Operating Expenses
Operating Expenses 4th Quarter FY03 = 70.5% of sales, down from 118.1% OPEX= $19.6 M, lowest spend level in 7 qtrs Total reduction in OPEX of $4.3M SG&A down $2.4 M R&D down $1.9M New indications development down $1.6M Year FY03 = 80.1% of sales, down from 119.4% OPEX =$83.7M Expenses flat from FY02
Slide 25: Q4FY03 vs. Q4 FY02
Q4FY03 vs. Q4 FY02 Sales increased $7.5 million (37%) Net Income increased $10.9 million (159%) to $4.0 million EPS increased $0.49 per share to $0.17 EPS exceeded guidance by $0.02 per share (13%) Net Income (Loss) Per Share FY2003 vs.FY2002 Sales increased $34.4 million (49%) Net Income increased
Slide 26: Balance Sheet Summary
Balance Sheet Summary Effective working capital management continued to minimize investment in accounts receivable (46 days) and inventory (annual turnover 2.7 times), and maximize year-end cash ( $43.6 million). In Q4 Cash flow as positive for the third consecutive quarter increasing by $4.0M over
Slide 27: FY04 Revised Guidance Summary
FY04 Revised Guidance Summary Preliminary Revised Sales At least $124M >20% annual growth $128M >22% annual growth Gross Margins At least 85% At least 85% OPEX < 80% of sales < 77% of sales Depression pre-launch No more than $8M No more than $7M Total New Indications Expenses No more than $16M No mo
Slide 28: FY04 Annual Sales Guidance
FY04 Annual Sales Guidance FY98 FY99 FY00 FY01 FY02 FY03 FY04G Worldwide Sales ($$ in Millions) We expect worldwide in FY04 to grow by at least 22% to over $128 million. That guidance implies a 89% sales CAGR since U.S. launch in 1997.
Slide 29: FY04 Quarterly Sales Guidance
FY04 Quarterly Sales Guidance Q1 Q2 Q3 Q4 Sales 26.51 29.151 33.675 38.904 $$'s in million"s We are projecting sales for Q1 to be approximately $26.5 million reflecting historical worldwide seasonality, the short-term effect of our annual week- long U.S. sales meeting and the recently completed U.S.
Slide 30: FY04 Annual Earnings Guidance
FY04 Annual Earnings Guidance FY04 guidance calls for a doubling of earnings including $7M ($0.28 per share) of incremental depression pre-launch spending. FY01 FY02 FY03 FY04G Net Earnings Per Share -1.31 -1.21 0.22 0.45 $0.22 Annual Earnings Per Share $0.45
Slide 31: FY04 Quarterly Earnings Guidance (EPS)
FY04 Quarterly Earnings Guidance (EPS) Q1 Q2 Q3 Q4 EPS 0.08 0.12 0.11 0.15 Quarterly earnings are anticipated to be at least $0.08 per fully diluted share in Q1, with quarterly earnings thereafter expected to be at least $0.10 per share including $7 million of budgeted depression pre-launch expenses
Slide 32: FY04: Increasing Profitability of Core Business Model
FY04: Increasing Profitability of Core Business Model In FY04, Cyberonics is planning to steadily improve the profitability, scalability and transferability of its core business model to accelerate penetration of the epilepsy market and realize the full potential of VNS Therapy in new indications. Q
Slide 33: FY04 Summary
FY04 Summary With or without depression, Cyberonics has emerged as a neuromodulation market leader in terms of predictability, sales growth, profitability and new device markets and indications development. With or without depression, Cyberonics' assets include (1) a strong intellectual property fra
Slide 34: FY03/4 Summary
FY03/4 Summary With or without depression, Cyberonics has emerged as a neuromodulation market leader in terms of predictability, sales growth, profitability and new device markets and indications development. In FY03, Cyberonics strengthened its core competencies/assets and matched those core compet
Slide 35: The Evolution of the CYBX Opportunity
The Evolution of the CYBX Opportunity: From Pioneering to Predictable and Profitable Growth With or Without Depression FY03: A Year for the Record Books FY04 Plan: Improving Productivity and Profitability to Increase Scalability and Transferability to Fully Realize Our Opportunities in Epilepsy and